Pilot Investigation of Stem Cells in Stroke
Pilot Investigation of Stem Cells in Stroke
The study is designed to test the safety of a manufactured neural stem cell line (CTX cells)
 delivered by injection into the damaged brains of male patients 60 years of age or over who
 remain moderately to severely disabled 6 months to 5 years following an ischemic stroke. In
 addition the trial will evaluate a range of potential efficacy measures for future trials.
 Treatment will involve a single injection of one of four doses of CTX cells into the
 patient's brain in a carefully controlled neurosurgical operation performed under general
 anesthetic. The trial is designed to treat 12 patients and measure outcomes over 24 months.
 Patients will be invited to participate in a long-term follow-up trial for a further 8 years.
Design: The trial is an open label, single administration, ascending dose, single site trial
 using CTX neural stem cells with 24-month patient monitoring following treatment.

 Pre-treatment selection of patients : Males aged ≥60 years with unilateral ischaemic stroke
 affecting sub-cortical white matter and/or basal ganglia 6 months to 5 years prior to entry
 into the study, with persistent unilateral hemiparesis, a minimum infarct diameter of 1 cm
 and stable neurological functional deficit as determined by the NIH Stroke Scale, (measured
 twice at least 1 month apart), will be eligible for treatment.

 Treatment: The CTX cells will be injected by stereotaxic procedures into the putamen region
 of the brain of the patient under general anesthesia with imaging guidance to locate
 injection site. Four ascending doses of CTX cells will be tested in 12 patients (4 dosage
 groups of three patients at each dose level receiving 2 million, 5 million, 10 million or 20
 million cells). Patients will be admitted to hospital the day before surgery and prepared for
 CTX cell implantation to take place. Patients will be discharged two days after surgery.

 One patient will be treated at a time. An independent Data Safety Monitoring Board (DSMB)
 will make the decision to continue dosing at each dose level following satisfactory review of
 the 28 day safety data for the first patient at that dose level; and to increase the dose to
 the next level following satisfactory review of the 3 month safety data for all three
 patients in the previous dose group.

 Post treatment follow-up of patients: There will be 6 scheduled visits to clinic for
 monitoring and neurofunctional testing and 5 scheduled telephone contacts to monitor adverse
 events (AEs) and concomitant medications over the 2 year follow-up period.

 End-points: The primary end-point of the trial is safety, measured by numbers of relevant
 Serious Adverse Events, health screening, neurological assessment and scanning abnormalities.
 The secondary aim is to evaluate various MRI and other test measures for their potential as
 efficacy markers for subsequent trials.

 Post trial follow up: All trial patients will be flagged by the National Health Service
 Central Register (NHSCR) Scotland for life-long follow-up. In addition, all patients will be
 invited to take part in an 8-year follow up trial requiring an annual review by a suitable
 physician.
Inclusion Criteria:

 -  Males

 -  60 years or over

 -  Unilateral ischemic stroke involving subcortical white matter or Basal Ganglia 6
 months to 5 years before entry

 -  NIHSS score minimum 6 with hemiparesis (2 or more for motor arm and leg)

 -  Neurologically stable for 2 m

 -  modified Rankin score of 2-4

 -  Fit for general anesthesia, neurosurgery

 -  Capacity to consent

 -  Infarct at least 1cm diameter

 Exclusion Criteria:

 -  Structural brain vascular lesions requiring surgery or increasing the risk of
 stereotaxic implantation

 -  Unstable medical conditions with expected survival <12 months

 -  Any medical condition that would impair participation (eg progressive neurological
 disorders, mental illness)

 -  Major surgery within 30 days

 -  Previous allogeneic tissue transplant

 -  MMSE < 24

 -  Epilepsy

 -  Coagulation disorders or anticoagulant treatment that cannot be interrupted

 -  Stimulants, botox, tamoxifen

 -  Contraindications to MRI